SEC Filing Analysis: ACTUATE THERAPEUTICS, INC. (N/A)

Executive Summary

• Trading Significance: High
• Key Takeaway: An affiliated venture capital fund, Kairos Venture Partners II, L.P., has filed a notice of proposed sale for 280,000 shares of common stock valued at approximately $2.13 million.
• Market Impact: This transaction is highly significant, representing 1.52% of the company's market capitalization and 1.2% of its outstanding shares, which could create notable selling pressure on the stock.

Company Information

Field	Value
Company	ACTUATE THERAPEUTICS, INC.
Ticker Symbol	Not Available in Filing
CIK	0001652935
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	Kairos Venture Partners II, L.P.
CIK	0001696711
Title/Position	N/A
Relationship	Affiliate

Transaction Details

Field	Value
Form Type	144
Transaction Date	2025-12-11 (Approximate)
Transaction Code	N/A (Form 144 Proposed Sale)
Security Type	Common Stock
Shares Involved	280,000
Price Per Share	~$7.60 (Calculated)
Total Value	$2,128,000
Shares Owned After	Not Stated
Ownership Type	Indirect

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$2,128,000
% of Market Cap	1.52%
Shares Transacted	280,000
% of Shares Outstanding	1.20%
Post-Transaction Ownership	Not Stated
Materiality Assessment	Highly Significant

Impact Evaluation

• Market Cap Context: For a company with a $140 million market cap, a single transaction of $2.13 million is substantial. It represents a material liquidity event that the market will need to absorb.
• Ownership Concentration: While the post-transaction ownership is not stated, this sale by an affiliated fund signals a reduction in exposure by a significant, informed entity.
• Transaction Significance: The sale is classified as 'Highly Significant' because it exceeds both the 1% of market cap and 0.5% of shares outstanding thresholds. Such a large proposed sale can influence investor sentiment and stock price dynamics.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: While a large sale can be perceived negatively, a Form 144 filing provides notice, allowing the market to prepare. The impact will depend on how the shares are sold (e.g., block trade vs. open market) and the prevailing demand for the stock. However, it introduces a significant supply overhang.

Volume & Sentiment

• Expected Volume Impact: A significant increase in trading volume is expected around the time of the sale as the 280,000 shares are transacted.
• Sentiment Indicator: Bearish
• Reasoning: The decision by an early, pre-IPO investor to liquidate a position of this size is typically interpreted as a bearish signal, suggesting the fund is realizing gains or sees limited near-term upside.

Investment Insights

Risk Factors

• Selling Pressure: The introduction of 280,000 shares to the market could create downward pressure on the stock price.
• Signaling: The sale by a venture capital fund may signal to the market that an informed, early investor is taking profits, which could dampen new investor enthusiasm.
• Further Sales: This filing could precede additional sales from the same fund or other early investors looking to exit their positions.

Key Takeaways

1. Significant Liquidation: An affiliated fund is planning a $2.13 million sale, which is a material event for a company of this size.
2. High Materiality: The transaction's size relative to market cap (1.52%) and shares outstanding (1.20%) makes it highly significant and warrants close monitoring.
3. Early Investor Exit: The shares were acquired in a 2019 pre-IPO investment, indicating this is a venture fund realizing its investment, a common but often bearish signal for the stock's short-term performance.

Additional Context

Transaction Notes

• The filing is a Form 144, which is a notice of proposed sale of securities, not a completed transaction. The sale is planned to occur on or around December 11, 2025.